PD-L1 Testing Defines New First-Line Option in TNBC
FDA approved sacituzumab govitecan plus pembrolizumab for first-line PD-L1 CPS ≥10 triple-negative breast cancer, expanding treatment options based on validated biomarker testing.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.